ASND - Ascendis Pharma A/S Stock Price and Quote

Index	-	P/E	-	EPS (ttm)	-10.90	Insider Own	0.07%	Shs Outstand	57.33M	Perf Week	-4.85%
Market Cap	4.85B	Forward P/E	-	EPS next Y	-0.01	Insider Trans	0.00%	Shs Float	57.29M	Perf Month	22.61%
Income	-609.50M	PEG	-	EPS next Q	-	Inst Own	123.56%	Short Float / Ratio	7.74% / 5.37	Perf Quarter	-22.78%
Sales	83.50M	P/S	58.04	EPS this Y	-48.50%	Inst Trans	3.26%	Short Interest	4.43M	Perf Half Y	-26.01%
Book/sh	3.20	P/B	26.81	EPS next Y	50.00%	ROA	-48.80%	Target Price	138.57	Perf Year	-3.31%
Cash/sh	11.11	P/C	7.72	EPS next 5Y	-	ROE	-152.70%	52W Range	64.33 - 134.52	Perf YTD	-29.76%
Dividend	-	P/FCF	-	EPS past 5Y	-23.10%	ROI	-73.50%	52W High	-36.23%	Beta	0.51
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	101.80%	Gross Margin	83.90%	52W Low	33.34%	ATR	3.80
Employees	797	Current Ratio	4.10	Sales Q/Q	394.10%	Oper. Margin	-	RSI (14)	41.90	Volatility	3.16% 4.31%
Optionable	Yes	Debt/Eq	3.02	EPS Q/Q	10.60%	Profit Margin	-	Rel Volume	0.47	Prev Close	89.75
Shortable	Yes	LT Debt/Eq	2.87	Earnings	Apr 27 AMC	Payout	-	Avg Volume	825.85K	Price	85.78
Recom	2.00	SMA20	-6.86%	SMA50	-4.90%	SMA200	-19.38%	Volume	379,250	Change	-4.42%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$151 → $108
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy	$174
Aug-30-22	Resumed	Berenberg	Buy	$166
Mar-28-22	Resumed	Wedbush	Outperform	$163
Mar-15-22	Upgrade	BofA Securities	Neutral → Buy	$148 → $161
Mar-01-22	Initiated	Citigroup	Buy	$187
Feb-14-22	Upgrade	Oppenheimer	Perform → Outperform	$170
Jan-06-22	Initiated	Cowen	Market Perform	$136
Dec-08-21	Initiated	Wells Fargo	Overweight	$176
Oct-20-21	Downgrade	BofA Securities	Buy → Neutral	$164 → $169
Mar-30-21	Downgrade	Oppenheimer	Outperform → Perform
Mar-11-21	Resumed	Stifel	Buy	$190
Dec-17-20	Initiated	Berenberg	Buy	$216
Sep-14-20	Resumed	JP Morgan	Overweight	$160
Mar-20-20	Initiated	Oppenheimer	Outperform	$199
Oct-11-19	Initiated	Morgan Stanley	Overweight	$128
Mar-25-19	Initiated	Evercore ISI	Outperform
Jan-24-19	Upgrade	Leerink Partners	Mkt Perform → Outperform

Show Previous Ratings

May-25-23 08:30AM	Ascendis Pharma to Host Oncology Program Update on May 31 (GlobeNewswire)
May-13-23 07:00PM	Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023 (GlobeNewswire)
May-03-23 04:15PM	Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference (GlobeNewswire) +6.48%
06:08AM	Need To Know: Analysts Are Much More Bullish On Ascendis Pharma A/S (NASDAQ:ASND) Revenues (Simply Wall St.)
May-01-23 11:45AM	Why Shares of Ascendis Pharma Are Climbing Monday (Motley Fool) +23.99%
07:00AM	Loading…
07:00AM	U.S. Food & Drug Administration Issues Complete Response Letter for TransCon PTH in Hypoparathyroidism (GlobeNewswire)
Apr-27-23 04:01PM	Ascendis Pharma Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-22-23 08:11AM	An Intrinsic Calculation For Ascendis Pharma A/S (NASDAQ:ASND) Suggests It's 20% Undervalued (Simply Wall St.)
Apr-13-23 08:30AM	Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27 (GlobeNewswire)
Apr-12-23 09:18AM	Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Apr-06-23 04:22PM	Why Ascendis Pharma Stock Is Crashing This Week (Motley Fool)
Apr-04-23 12:43PM	Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies (Zacks)
Apr-03-23 04:07PM	Ascendis Stock Plunges As FDA Identifies Deficiencies In Company's New Drug Application (Investor's Business Daily) -32.07%
01:10PM	Ascendis Pharma Flags Regulatory Delay In US For Its Hypoparathyroidism Candidate (Benzinga)
12:28PM	Why Ascendis Pharma Stock Is Plunging Today (Motley Fool)
07:05AM	Loading…
07:05AM	Ascendis Pharmas Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon IL-2 / Accepted for Online Publication at ASCO 2023 (GlobeNewswire)
07:00AM	Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH in Hypoparathyroidism (GlobeNewswire)
Mar-17-23 03:35AM	Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last? (Zacks)
Mar-10-23 08:00AM	Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-20-23 08:08AM	Ascendis Pharma A/S (NASDAQ:ASND) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-18-23 07:23AM	Ascendis Pharma Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Feb-16-23 04:01PM	Ascendis Pharma Reports Full Year 2022 Results (GlobeNewswire)
Feb-07-23 08:00AM	Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16 (GlobeNewswire)
Jan-30-23 11:46PM	What Makes Ascendis Pharma A/S (ASND) an Attractive Investment Choice? (Insider Monkey)
Jan-08-23 05:00PM	Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:30AM	Ascendis Pharma's (NASDAQ:ASND) growing losses don't faze investors as the stock climbs 3.8% this past week (Simply Wall St.)
Jan-04-23 08:00AM	Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharmas TransCon PTH for Eligible U.S. Adult Patients with Hypoparathyroidism (GlobeNewswire)
Jan-03-23 08:00AM	Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-22 08:38PM	Heres the Reason for the Healthy Performance of Ascendis Pharma A/S (ASND) (Insider Monkey)
Dec-05-22 08:00AM	Ascendis Pharma to Initiate TransCon PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism (GlobeNewswire)
08:30AM	Loading…
Nov-22-22 08:30AM	Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-22 07:00AM	Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon PTH in Adult Patients with Hypoparathyroidism (GlobeNewswire) -16.45%
05:34AM	Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism (Benzinga)
Nov-13-22 06:15PM	Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharmas Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years (GlobeNewswire)
Nov-11-22 12:10PM	Dose Escalation Data from transcendIT-101, Ascendis Pharmas Phase 1/2 Trial of TransCon TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022 (GlobeNewswire)
Nov-02-22 04:01PM	Ascendis Pharma Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-31-22 08:00AM	FDA Accepts for Priority Review Ascendis Pharmas NDA for TransCon PTH in Adult Patients with Hypoparathyroidism (GlobeNewswire)
Oct-26-22 08:00AM	Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2 (GlobeNewswire)
Oct-12-22 09:55AM	Does Ascendis Pharma AS (ASND) Have the Potential to Rally 35% as Wall Street Analysts Expect? (Zacks)
Oct-11-22 11:38PM	15 Most Valuable Danish Companies in the World (Insider Monkey)
Oct-03-22 08:00AM	Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors (GlobeNewswire)
Sep-12-22 08:00AM	New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharmas TransCon PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022 (GlobeNewswire)
Sep-01-22 08:00AM	Ascendis Pharma A/S Announces Upcoming Investor Presentations in September (GlobeNewswire)
Aug-31-22 11:12AM	Analysts Pound the Table on These 3 Strong Buy Stocks; See Over 70% Upside Potential (TipRanks)
08:27AM	Ascendis Pharma Submits TransCon PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism (GlobeNewswire)
Aug-10-22 04:01PM	Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-09-22 08:06AM	Ascendis Pharma Presents a Mixed Technical Picture Ahead of Earnings (TheStreet.com) -5.84%
Aug-04-22 08:00AM	Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10 (GlobeNewswire)
Aug-01-22 07:00AM	While Ascendis Pharma (NASDAQ:ASND) shareholders have made 205% in 5 years, increasing losses might now be front of mind as stock sheds 3.4% this week (Simply Wall St.)
Jun-16-22 11:42AM	Ascendis Pharma (NASDAQ:ASND) Is Using Debt Safely (Simply Wall St.) -5.52%
Jun-07-22 08:00AM	Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022 (GlobeNewswire)
May-23-22 08:00AM	Positive Results from VISENs Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharmas Phase 3 Height Trial (GlobeNewswire)
08:00AM	Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments (GlobeNewswire)
May-12-22 04:09PM	Ascendis Reverses Its Losses After A Key Drug Misses Sales Forecasts (Investor's Business Daily)
May-11-22 04:01PM	Ascendis Pharma A/S Reports First Quarter 2022 Financial Results (GlobeNewswire) -5.52%
02:40AM	Why Ascendis Pharma (ASND) Might Surprise This Earnings Season (Zacks)
May-10-22 11:13AM	Vermilion Energy (VET) to Report Q1 Earnings: What's in Store? (Zacks)
May-09-22 08:00AM	Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference (GlobeNewswire) -5.03%
May-04-22 04:05PM	Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11 (GlobeNewswire)
May-02-22 11:08AM	We Think Ascendis Pharma (NASDAQ:ASND) Can Afford To Drive Business Growth (Simply Wall St.)
May-01-22 07:00AM	Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May (GlobeNewswire)
Apr-04-22 06:00AM	Ascendant Provides an Update on Its Ongoing Feasibility Study and Related Activities at Its Lagoa Salgada Project, Portugal (GlobeNewswire)
Mar-24-22 10:41PM	Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering (GlobeNewswire)
Mar-23-22 04:01PM	Ascendis Pharma Announces Proposed Convertible Senior Notes Offering (GlobeNewswire) -5.03%
Mar-14-22 07:57AM	Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints (Benzinga)
Mar-13-22 05:53PM	Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints (GlobeNewswire)
Mar-03-22 09:30AM	Should You Buy Ascendis Pharma (ASND) Ahead of Earnings? (Zacks)
Mar-02-22 04:01PM	Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-22 08:00AM	Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2 (GlobeNewswire)
03:30AM	Artisan Partners Remains Quite Optimistic in Ascendis Pharma (ASND) (Insider Monkey)
Feb-10-22 04:05PM	Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-08-22 01:38PM	CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ... (GuruFocus.com)
04:46AM	Ascendis Pharma's (NASDAQ:ASND) investors will be pleased with their incredible 399% return over the last five years (Simply Wall St.)
Feb-04-22 05:38PM	Capital Asset Advisory Services LLC Buys iShares Russell 3000 ETF, iShares 7-10 Year Treasury ... (GuruFocus.com) +5.15%
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... (GuruFocus.com)
Jan-25-22 07:09AM	Ascendis Pharma AS (ASND) Surges 6.5%: Is This an Indication of Further Gains? (Zacks)
Jan-24-22 12:48PM	Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA (Zacks) +6.53%
Jan-14-22 11:34AM	Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD (Zacks)
Jan-13-22 11:44AM	Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval (Benzinga)
08:00AM	Ascendis Pharma A/S Receives European Approval for TransCon hGH for Pediatric Growth Hormone Deficiency (GlobeNewswire)
Jan-10-22 08:00AM	Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-22 08:00AM	Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-17-21 11:38PM	VY(R) Invesco Oppenheimer Global Portfolio Buys Analog Devices Inc, Splunk Inc, Danaher Corp, ... (GuruFocus.com)
Dec-14-21 08:00AM	Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline (GlobeNewswire)
Dec-13-21 04:38PM	Invesco V.I. Global Fund Buys Analog Devices Inc, Dassault Systemes SE, Splunk Inc, Sells , ... (GuruFocus.com)
Dec-11-21 06:25PM	Hedge Funds Are Dumping Ascendis Pharma A/S (ASND) (Insider Monkey)
Dec-09-21 08:38PM	NVIT Wells Fargo Discovery Fund Buys Lightspeed Commerce Inc, Cognex Corp, Bumble Inc, Sells ... (GuruFocus.com)
Dec-08-21 07:38PM	Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ... (GuruFocus.com)
Dec-07-21 05:41PM	Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14 (GlobeNewswire)
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-23-21 11:07AM	Heres Why Artisan Partners Increased its Ascendis Pharma (ASND) Position (Insider Monkey)
Nov-19-21 07:40AM	Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks (Benzinga)
Nov-18-21 04:42PM	Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism (GlobeNewswire)
Nov-17-21 04:05PM	Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference (GlobeNewswire)
Nov-15-21 11:00AM	Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing (Zacks)
08:00AM	Ascendis Pharma A/S - Share Repurchase Program Update (GlobeNewswire)
Nov-12-21 07:22AM	Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon hGH for Patients with Pediatric Growth Hormone Deficiency (GlobeNewswire)
Nov-10-21 10:00PM	Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript (Motley Fool)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience